Skip to content
BOE-A-2026-4956 ·2 March 2026 ·Resolution Medium impact
Corporate

Publication of agreement between Carlos III Health Institute and FEDER Foundation for rare disease research evaluation

The Resolution of 23 February 2026 publishes the agreement signed on 17 February 2026 between the Carlos III Health Institute and the FEDER Foundation for the evaluation of research proposals on rare diseases. This arrangement is governed by Article 48.8 of Law 40/2015, and its publication in the BOE formally initiates the evaluation process. There are no changes to submission conditions or evaluation procedures; only the legal agreement between the parties is formalised.

In 2 key points

  1. An agreement between ISCIII and FEDER is published for the formal evaluation of research proposals on rare diseases (art. 48.8 Ley 40/2015)
  2. The agreement was signed on 17 February 2026 and is included as an annex (anexo de la resolución)

How it affects those involved

Researchers and entities submitting proposals for rare disease research may benefit from formal evaluation by ISCIII under the signed agreement. Public administration does not alter submission deadlines or procedures. The agreement does not affect companies, self-employed individuals, or general private parties.

Lifecycle

2026-03-02PublishedPublished in the BOE
2026-03-02Into forceComes into force (resolución de 23 de febrero de 2026)
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The corporate team reviews your specific situation.

Talk to the corporate team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BM Consulting.
Email
Contact